20 June 2014 : Original article
Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation
Tomasz UrbanowiczABCDEF, Hanna Baszyńska-WachowiakBC, Marcin LigowskiBCD, Ewa Straburzyńska-MigajBCD, Marcin MisterskiB, Marek JemielityABCDDOI: 10.12659/AOT.890268
Ann Transplant 2014; 19:295-299
Abstract
BACKGROUND: A new formulation of tacrolimus that is characterized by prolonged release has been developed to facilitate treatment and patient compliance. Initial therapy with prolonged release formula in heart transplantation is not widely accepted.
MATERIAL AND METHODS: We enrolled 19 patients into a randomized analysis divided into 2 groups with different initial regimens. There were 8 patients with a mean age of 44±13 years treated by Advagraf, and 11 patients with a mean age of 41±9 years treated by Prograf. Serum concentration of immunosuppressive drug was followed by its oral dosage and endomyocardial biopsy results. Arterial hypertension, kidney function, and incidence of diabetes mellitus were recorded.
RESULTS: There were no perioperative deaths. The risk of acute rejection within 6 months following surgery was 1 (2%) in the Advagraf group and 1 (1.5%) in the Prograf group. Although the serum tacrolimus results were comparable between groups, the drug’s daily dosages were different after 6 months of therapy (3±1 mg in the Advagraf group and 6±2 mg in the Prograf group (p<0.05). The low rate of adverse effects throughout the study was noted.
CONCLUSIONS: Prolonged-release tacrolimus formula is an efficient immunosuppressant in heart transplantation. Its initial application after surgery has low risk of adverse effects with similar results to conventional formula.
Keywords: Heart Transplantation, Biopsy, Tacrolimus
In Press
Original article
Impact of Preoperative Treatment on Donor Hepatic Steatosis in Living Donor Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.947772
Original article
Effects of Donor-Recipient Race Matching on Kidney Transplant SurvivalAnn Transplant In Press; DOI: 10.12659/AOT.947720
Most Viewed Current Articles
03 Jan 2023 : Original article 6,996
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...DOI :10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
15 Aug 2023 : Review article 6,986
Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ TransplantationDOI :10.12659/AOT.939750
Ann Transplant 2023; 28:e939750
16 May 2023 : Original article 6,742
Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...DOI :10.12659/AOT.939258
Ann Transplant 2023; 28:e939258
28 May 2024 : Original article 6,162
Effect of Dexmedetomidine Combined with Remifentanil on Emergence Agitation During Awakening from Sevoflura...DOI :10.12659/AOT.943281
Ann Transplant 2024; 29:e943281